House committee questions Eli Lilly, Sanofi and Novo Nordisk as insulin prices remain 'unacceptably high'

House Energy & Commerce Committee leaders sent three letters on Thursday to execs at Eli Lilly, Sanofi and Novo Nordisk, raising concerns that despite their supposed concern over the past two years with the price of insulin, the price still remains “unacceptably high.”